1. Introduction {#sec1}
===============

In 2005, Bouillanne et al. created a new index of malnutrition, called the Geriatric Nutritional Risk Index (GNRI), which is based on three parameters: height, body weight, and serum albumin level. The GNRI was calculated as follows: \[1.489 × albumin (g/L)\] + \[41.7 × (body weight/ideal body weight)\]. The ratio of body weight to ideal body weight was set to 1 when the patient\'s body weight exceeded the ideal body weight \[[@B1]\]. This study firstly reported that GNRI was a simple and accurate tool for predicting the risk of morbidity and mortality in hospitalized elderly patients \[[@B1]\]. Thereafter, the GNRI has also been widely used to assess the nutritional status and also reported to be associated with adverse outcomes in a variety of human pathological conditions. For instance, the low-GNRI group was reported to be associated with a higher rate of postoperative complications and longer length of hospital stay when compared with those in the high-GNRI group in patients who underwent abdominal surgery \[[@B2]\], an increased risk of all-cause and cardiovascular mortality in chronic hemodialysis patients \[[@B3]\], all-caused death and cardiac death in patients who underwent percutaneous coronary intervention \[[@B4]\], poor prognosis (including higher risk of mortality, metastatic infection, and organ dysfunction) in pyogenic liver abscess patients \[[@B5]\], short-term hospital mortality in older patients with sepsis \[[@B6]\], and long-term survival plus cardiovascular/limb events in patients with peripheral arterial disease \[[@B7]\].

Malnutrition is a common problem among cancer patients, and cancer-associated malnutrition is associated with increased morbidity and mortality \[[@B8]\]. Meanwhile, the occurrence and development of cancers have been shown to be associated with aging \[[@B9]\] and the elderly subjects are considered to be susceptible with more risk of nutritional problems \[[@B10]\]. As a simple and well-established nutritional assessment tool, the GNRI is also reported to be a significant prognostic factor for various malignancies recently.

However, the prognostic significance of GNRI on human malignancies has not been thoroughly clarified. Therefore, this meta-analysis was conducted to verify the prognostic role of GNRI in human malignancies based on available evidence.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

Our literature search strategy was performed according to the preferred reporting items for systemic reviews and meta-analysis (PRISMA) statement criteria \[[@B11]\]. We retrieved literatures about the prognostic significance of the GNRI in patients with malignancies, which were published before July 27, 2019, in available databases, including *PubMed*, *Web of Science*, *Cochrane library*, *Chinese CNKI*, and *Chinese Wan-fang*. We used the following search words: "*Geriatric Nutritional Risk Index*," "*GNRI*," and "*cancer*," "*carcinoma*," "*leukemia*," and "*lymphoma*." The search strategy in Cochrane was "*Geriatric Nutritional Risk Index in Abstract OR GNRI in Abstract*." The search strategy in PubMed was "(*Geriatric Nutritional Risk Index\[Title/Abstract\]) OR GNRI\[Title/Abstract\]*." The search strategy in Web of Science was "*TS=(Geriatric Nutritional Risk Index in Abstract OR GNRI)*." The reference lists of retrieved literatures were also screened to identify more potential studies.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies included in this meta-analysis were required to meet all of the following criteria: (1) reporting the prognostic role of the GNRI in human malignancy; (2) analyzing prognostic outcomes, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), or progression-free survival (PFS); and (3) providing the hazard ratio (HR) and 95% its confidence interval (CI) for prognosis (or calculable according to data provided in the original literature). The studies were excluded if they met any of the following items: (1) case report, (2) review article, (3) redundant publication, and (4) HR and 95% CI unacquirable.

2.3. Data Extraction {#sec2.3}
--------------------

This procedure was conducted by two authors (Da-wei Sun and Lin An), and disagreements were resolved by consensus among all the participating authors. The hazard ratios (HRs) and 95% confidence intervals (CIs) for prognosis were our main concern. When the prognostic results were provided in the Kaplan-Meier curve, Engauge Digitizer 4.1 was used to read and calculate the number of death/recurrence in each group. Then according to the total numbers of observed deaths/recurrences and the number of samples in each group, we calculated the HR and 95% CI by following Tierney et al.\'s method \[[@B12]\]. The other important items included the 1^st^ author information, publication year, patient country, cancer species, sample capacity, dividing line for GNRI, HR origin, analytic methodology, and follow-up interval. For studies based on the same study center, we collected data from the study with the largest sample size. Here, we declared that the data extraction method in this part was nearly the same as that used in our team\'s previously published meta-analysis researches.

2.4. Statistics Analysis {#sec2.4}
------------------------

Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to compare the prognostic outcomes, including OS, CSS, DFS, and PFS. Chi-square test and *I*^2^ were used to check the interstudy heterogeneity, with significance set at *p* \< 0.1 or *I*^2^ \> 50%. A random effects model was employed in case of significant heterogeneity; otherwise, a fixed effects model was applied. Publication bias was examined by both Begg\'s and Egger\'s tests \[[@B13], [@B14]\]. In this meta-analysis, a *p* value \< 0.05 was considered significant. Meanwhile, we performed a sensitivity analysis by removing each study to evaluate the effect of an individual study on the overall pooled HRs. Here, we also declared that the statistics analysis method in this part was nearly the same as that used in our team\'s previously published meta-analysis researches.

3. Results {#sec3}
==========

3.1. Systemic Review for Included Studies {#sec3.1}
-----------------------------------------

[Figure 1](#fig1){ref-type="fig"} illustrates the searching procedure of potential included studies. In the end, a total of 15 studies with 8,046 cases were identified through systemic search \[[@B15]--[@B29]\]. Five studies were based on patients with hematological malignant tumors \[[@B15]--[@B19]\], 4 studies were based on esophageal cancers \[[@B20]--[@B23]\], 2 studies were based on renal cell carcinoma \[[@B24], [@B25]\], and 4 studies were based on hepatocellular carcinoma, prostate cancer, pancreatic cancer, and lung cancer respectively \[[@B26]--[@B29]\]. Among these studies, two studies reported HRs for prognosis by two subsets in each study \[[@B23], [@B27]\]. On the basis of population origin, all the studies were based on Asian countries (1 in Korea, 9 in Japan, and 5 in China). The publication year happened between 2017 and 2019, the study sample size varied from 63 to 4,591, and the demarcation for GNRI ranged from 92 to 99.2. The other characteristics of the included studies, such as age, gender ratio, primary therapy, endpoint, source of HR, analytic method of HR, and follow-up interval, could be seen in [Table 1](#tab1){ref-type="table"}.

3.2. Meta-Analysis for OS {#sec3.2}
-------------------------

The prognostic value of GNRI for OS was available in 13 studies (including one study consisting of two subcohorts) with 3,023 cases. On the basis of random effects model (*I*^2^ = 84.2%, *p* ≤ 0.001), the GNRI was significantly associated with OS (HR = 1.95, 95% CI: 1.49-2.56, *p* ≤ 0.001) ([Figure 2](#fig2){ref-type="fig"}). As a result, patients with low GNRI suffered from poor OS when compared with patients with normal GNRI.

3.3. Meta-Analysis for CSS {#sec3.3}
--------------------------

Five studies (including one study consisting of two subcohorts) with 5,743 cases reported the prognostic role of GNRI for CSS. According to a fixed effects model (*I*^2^ = 14.4%, *p* = 0.322), the GNRI was also significantly relevant to CSS (HR = 1.81, 95% CI: 1.49-2.19, *p* ≤ 0.001) ([Figure 3](#fig3){ref-type="fig"}). That is, patients with low GNRI suffered from poor CSS when compared with patients with normal GNRI.

3.4. Meta-Analysis for DFS {#sec3.4}
--------------------------

The correlation of the GNRI with DFS was available in 6 studies (including one study consisting of two subcohorts) with 5,625 cases. Meta-analysis results from a random effects model (*I*^2^ = 70.5%, *p* = 0.002) evinced that GNRI was also significantly correlated with DFS (HR = 1.67, 95% CI: 1.28-2.17, *p* ≤ 0.001) ([Figure 4](#fig4){ref-type="fig"}). That is, patients with low GNRI suffered from poor DFS when compared with patients with normal GNRI.

3.5. Meta-Analysis for PFS {#sec3.5}
--------------------------

The association between GNRI and PFS was investigated by only 2 studies with 725 cases. Heterogeneity could be identified among these 2 studies (*I*^2^ = 50.8%, *p* = 0.154); thus, a random effects model was adopted to perform this meta-analysis. Meta-analysis results evinced that low GNRI was associated with PFS (HR = 1.68, 95% CI: 1.28-2.21, *p* ≤ 0.001) ([Figure 5](#fig5){ref-type="fig"}), suggesting that patients with low GNRI suffered from poor PFS when compared with patients with normal GNRI.

3.6. Stratification Analysis for the Meta-Analysis with OS {#sec3.6}
----------------------------------------------------------

Considering that more than ten studies were included in the meta-analysis with OS and heterogeneity was identified in this meta-analysis result, thus, stratification analysis was conducted in this process. As shown in [Table 2](#tab2){ref-type="table"}, despite the variation of publishing year, population country, sample capacity, cancer system, primary therapy, GNRI dividing line, HR source, or analytic methodology, the low GNRI was associated with poor OS in human malignancies. Nevertheless, no heterogeneity could be found the subgroup meta-analysis when defined by study sample size \< 240 ([Figure 6(a)](#fig6){ref-type="fig"}), GNRI value \< 98 ([Figure 6(b)](#fig6){ref-type="fig"}), HR source from crude origin ([Figure 6(c)](#fig6){ref-type="fig"}), or multivariate analysis ([Figure 6(d)](#fig6){ref-type="fig"}).

3.7. Sensitivity Analyses {#sec3.7}
-------------------------

To examine the robustness of our results, sensitivity analysis was performed by removing each individual included study. Omitting any of the included studies did not change the combined meta-analysis effect of GNRI on the HRs for OS, CSS, DFS, or PFS (Figures [7(a)](#fig7){ref-type="fig"}--[7(d)](#fig7){ref-type="fig"}). That is to say, our findings were robust across sensitivity analyses.

3.8. Publication Bias {#sec3.8}
---------------------

For the meta-analysis with OS, no publication bias was found by Begg\'s test (*p* = 0.155), but publication bias was found by Egger\'s test (*p* ≤ 0.05). Publication bias was not examined in the other meta-analysis, since the included study number was less than ten.

4. Discussion {#sec4}
=============

With the ratio of older people continuing to rise, designing age-specific nutritional policies is a matter of necessity \[[@B30]\]. As a dichotomous index, the GNRI combines two nutritional indicators: albumin and actual weight compared with desirable weight, and the GNRI seems to account for both acute and chronic reasons of nutrition-related outcomes \[[@B30]\]. When compared with Mini Nutritional Assessment (MNA) validated for grading nutritional status in the elderly, the GNRI has been reported to show poor agreement in nutritional assessment but appeared to better predict outcome \[[@B31]\].

To our knowledge, this present meta-analysis firstly evinced that lower GNRI is associated with poor prognosis in human malignancies. Based on current evidence, our meta-analysis exploited 15 studies with 8,046 malignancy cases. Meta-analysis results proved that low GNRI was associated with poor OS, poor CSS, poor DFS, and poor PFS, indicating that malignancy patients with low GNRI would suffer from reduced survival rate and increased recurrence rate. Meanwhile, stratified meta-analysis showed that low GNRI was associated with poor OS, though the publishing year, population country, sample capacity, cancer system, primary therapy, GNRI dividing line, HR source, and analytic methodology varied between different groups.

As a new nutrition-related risk assessment toll, the GNRI was also reported to be associated with postoperative complications in cancer patients (consisting of esophageal cancer, gastric cancer, liver cancer, gallbladder cancer, pancreatic cancer, and colon cancer) after abdominal surgery \[[@B2], [@B32]\]. Additionally, the preoperative GNRI was also reported to be a risk factor for surgical site infection in patients with soft-tissue sarcoma resection \[[@B33]\]. Taking all these results together, as an indicator of nutritional assessment, the GNRI is associated with adverse outcomes in human malignancies.

The obvious limitation for our meta-analysis is heterogeneity, especially in the meta-analysis with OS and DFS. However, no heterogeneity could be found in the subgroup meta-analysis using the studies defined by study sample size \< 240, GNRI value \< 98, HR source from crude origin, or multivariate analysis. Due to the small number of included studies in the meta-analysis with DFS, stratified analysis was not conducted in this part. The minor limitation for our meta-analysis is publication bias, which was found in the meta-analysis with OS. Nevertheless, the combined meta-analysis effect of GNRI on the HRs for OS, CSS, DFS, and PFS was not altered during the sensitivity analysis. Finally, we must declare that the data extraction, statistics analysis, and stratified analysis methods used in this research were nearly the same as those used in our team\'s previously published meta-analysis researches \[[@B34], [@B35]\]. Therefore, there was a textual overlap between this present research and our previously published researches.

5. Conclusion {#sec5}
=============

In summary, GNRI is associated with poor prognosis in human malignancies, and GNRI should be used as a predictive indicator of adverse outcomes during malignancy treatment.

We appreciated all the authors who performed the 15 included studies used in this meta-analysis. Without their previously published work, we could not draw our conclusions by meta-analysis.
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###### 

Summary characteristics of included studies in this meta-analysis.

  Author information           Year   Country   Cancer species             No. of patients   Age                  Gender ratio   Primary therapy             Cut-off for GNRI (no-risk/risk)   Endpoint                        HR and 95% CI                   Source of HR   Analytic method   Follow-up interval (months)
  ---------------------------- ------ --------- -------------------------- ----------------- -------------------- -------------- --------------------------- --------------------------------- ------------------------------- ------------------------------- -------------- ----------------- -----------------------------
  Konishi et al. \[[@B15]\]    2019   Japan     Acute myeloid leukemia     63                \>50                 21/42          Stem cell transplantation   98 (31/32)                        OS, DFS                         OS HR: 2.30 (1.19-4.46)         Data           Univariate        Median 33.9 (0.6-68.1)
                                                                                                                                                                                               DFS HR: 2.18 (1.11-4.26)        Data                            Univariate                       
  Mizuno et al. \[[@B16]\]     2019   Japan     Follicular lymphoma        130               Median 67 (32-91)    70/60          Chemotherapy                99.2 (96/34)                      OS                              OS HR: 5.65 (2.66-12.00)        Data           Univariate        Median 52
  Li et al. \[[@B17]\]         2018   China     DLBCL                      267               NR                   121/156        Chemotherapy                98 (162/105)                      OS                              OS HR: 0.81 (0.44-1.48)         Crude          Multivariate      Up to 72
  Kanemasa et al. \[[@B18]\]   2018   Japan     DLBCL                      476               Median 68 (27-97)    210/266        Chemotherapy                96.8 (221/255)                    OS, PFS                         OS HR: 2.05 (1.31-3.22)         Crude          Multivariate      Median 45
                                                                                                                                                                                               PFS HR: 1.93 (1.47-2.53)        Data                            Univariate                       
  Yang et al. \[[@B19]\]       2018   China     DLBCL                      249               Median 60 (18-85)    107/142        Chemotherapy                96.6 (136/113)                    OS, PFS                         OS HR: 1.28 (0.79-2.06)         Crude          Multivariate      Median 16 (0-51)
                                                                                                                                                                                               PFS HR: 1.46 (1.11-1.91)        Data                            Univariate                       
  Yamana et al. \[[@B20]\]     2018   Japan     ESCC                       216               NR                   NR             Resection                   92 (153/63)                       OS                              OS HR: 2.44 (1.59-3.70)         Crude          Univariate        Up to 60
  Kubo N \[[@B21]\]            2018   Japan     EC                         240               Mean 63.3 (66-113)   44/196         Resection                   92(196/44)                        OS, CSS                         OS HR: 1.69 (1.04-2.74)         Crude          Multivariate      Up to 60
                                                                                                                                                                                               CSS HR: 1.60 (0.91-2.82)        Crude                           Multivariate                     
  Migita et al. \[[@B22]\]     2018   Japan     ESCC                       137               NR                   21/116         Resection                   98 (92/45)                        OS, DFS                         OS HR: 2.10 (1.18-3.72)         Crude          Multivariate      Up to 60
                                                                                                                                                                                               DFS HR: 1.23 (1.00-1.51)        Data                            Univariate                       
  Bo et al. \[[@B23]\]         2016   China     ESCC                       239               Mean 67.9 (60-88)    89/150         Radiotherapy                98 (184/55)                       OS                              OS HR: 1.69 (1.02-2.80) sub1    Crude          Multivariate      Up to 60
                                                                                                                                                                                               OS HR: 2.70 (1.51-4.82) sub2    Crude                           Multivariate                     
  Li et al. \[[@B24]\]         2018   China     Hepatocellular carcinoma   261               Median 68 (67-70)    46/215         Resection                   98 (197/64)                       OS, DFS                         OS HR: 1.05 (0.97-1.14)         Data           Univariate        Up to 60
                                                                                                                                                                                               DFS HR: 1.29 (1.06-1.57)        Data                            Univariate                       
  Hu et al. \[[@B25]\]         2019   China     Pancreatic cancer          265               NR                   109/156        Resection                   98 (170/95)                       OS                              OS HR: 1.54 (1.12-2.12)         Crude          Multivariate      Up to 60
  Miyake et al. \[[@B26]\]     2017   Japan     Renal cell carcinoma       432               NR                   155/277        Resection                   98 (325/107)                      CSS, DFS                        CSS HR: 3.37 (1.86-6.14)        Data           Univariate        Up to 100
                                                                                                                                                                                               DFS HR: 1.52 (1.04-2.22)        Data                            Univariate                       
  Kang et al. \[[@B27]\]       2019   Korea     Renal cell carcinoma       4591              NR                   1224/3367      Resection                   98 (3859/732)                     CSS, DFS                        CSS HR: 1.67 (1.19-2.34) sub1   Crude          Multivariate      Median 37 (18-68)
                                                                                                                                                                                               CSS HR: 1.61 (1.13-2.28) sub2   Crude                           Multivariate                     
                                                                                                                                                                                               DFS HR: 1.33 (0.82-2.17) sub1   Crude                           Multivariate                     
                                                                                                                                                                                               DFS HR: 3.18 (2.00-5.06) sub2   Crude                           Multivariate                     
  Okamoto et al. \[[@B28]\]    2018   Japan     Prostate cancer            339               Median 72            0/339          Androgen-deprivation        92 (273/66)                       OS, CSS                         OS HR: 1.80 (1.13-2.87)         Crude          Multivariate      Median 26 (12-53)
                                                                                                                                                                                               CSS HR: 1.76 (1.04-2.98)        Crude                           Multivariate                     
  Shoji et al. \[[@B29]\]      2017   Japan     Lung cancer                141               Median 68 (37-86)    80/61          Resection                   98 (119/22)                       OS, CSS, DFS                    OS HR: 4.58 (2.36-8.87)         Data           Univariate        Median 58 (0-94)
                                                                                                                                                                                               CSS HR: 3.09 (0.98-9.68)        Data                            Univariate                       
                                                                                                                                                                                               DFS HR: 4.03 (1.45-10.73)       Crude                           Multivariate                     

Abbreviations: DLBCL: diffuse large B cell lymphoma; NR: no reported; ESCC: esophageal squamous cell carcinoma; EC: esophageal cancer; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; PFS: progression-free survival; HR: hazard ratio.

###### 

Stratification analysis for the meta-analysis with overall survival (OS) in patients with malignancies.

  Subgroup                 No. of studies   No. of patients without risk   No. of patients at risk   Pooled HR (95% CI)   Heterogeneity   
  ------------------------ ---------------- ------------------------------ ------------------------- -------------------- --------------- --------
  Altogether               13               2,030                          993                       2.01 (1.49-2.71)     85.0            ≤0.001
  Publishing time                                                                                                                         
   ≥2018                   10               1,565                          811                       1.86 (1.38-2.51)     84.4            ≤0.001
   \<2018                  3                465                            182                       2.21 (1.31-3.75)     69.3            0.021
  Country                                                                                                                                 
   Japan                   8                1,181                          561                       2.40 (1.86-3.10)     44.7            0.081
   China                   5                849                            432                       1.43 (1.08-1.90)     72.2            0.031
  Sample capacity                                                                                                                         
   ≥240                    7                1,355                          742                       1.45 (1.13-1.85)     70.5            0.002
   \<240                   6                675                            251                       2.66 (2.00-3.55)     42.6            0.107
  Dividing line for GNRI                                                                                                                  
   ≥98                     8                1,051                          452                       2.07 (1.41-3.03)     86.9            ≤0.001
   \<98                    5                979                            541                       1.84 (1.49-2.28)     6.3             0.371
  Cancer system                                                                                                                           
   Hematological           5                646                            539                       2.02 (1.27-3.20)     69.4            0.011
   Digestive               6                992                            366                       1.74 (1.25-2.43)     84.0            ≤0.001
   Urinary                 1                273                            66                        1.80 (1.13-2.87)     ---             ---
   Respiratory             1                119                            22                        4.58 (2.36-8.88)     ---             ---
  Primary therapy                                                                                                                         
   Resection               6                927                            333                       1.90 (1.25-2.88)     88.6            ≤0.001
   Chemotherapy            4                615                            507                       1.97 (1.12-3.49)     76.3            0.005
   Radiotherapy            1                184                            55                        2.09 (1.32-3.30)     ---             ---
   Others                  2                304                            98                        1.95 (1.33-2.86)     0.0             0.552
  HR source                                                                                                                               
   Crude                   9                1,587                          841                       1.78 (1.54-2.06)     0.00            0.441
   Data                    4                443                            152                       2.71 (1.06-6.90)     92.9            ≤0.001
  Analytic method                                                                                                                         
   Univariate              5                596                            215                       2.62 (1.28-5.35)     92.7            ≤0.001
   Multivariate            8                1,434                          778                       1.70 (1.46-1.99)     0.0             0.590
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